Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1254-1260

  Lai, Chung Chih ^a   Hung, Chien Ching ^b   Chen, Mao Yuan ^b   Sun, Hsin Yun ^b   Lu, Ching Lan ^b   Tseng, Yu Tzu ^b   Chang, Shu Fang ^c   Su, Yi Ching ^c   Liu, Wen Chun ^b   Hsieh, Chia Yin ^b   Wu, Pei Ying ^b   Chang, Sui Yuan ^b,c   Chang, Shan Chwen ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Genotypic resistance mutations; Highly active antiretroviral therapy; HIV infection

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; TAIWAN; TRANSMITTED DRUG RESISTANCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREVALENCE; RNA, VIRAL; TAIWAN; TREATMENT OUTCOME;

EID: 84859618898     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr601     Document Type: Article

References (39)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-4.
2. von Wyl V, Yerly S, Böni J et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167: 1782-90.
3. Bansi L, Geretti AM, Dunn D et al. Impact of transmitted drug-resistance on treatment selection and outcome of first-line highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2010; 53: 633-9.
4. Pillay D, Bhaskaran K, Jurriaans S et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20: 21-8.
5. Bartmeyer B, Kuecherer C, Houareau C et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS ONE 2010; 5: e12718.
6. Bannister WP, Cozzi-Lepri A, Clotet B et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008; 48: 324-33.
7. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331: 1368.
8. Wheeler WH, Ziebell RA, Zabina H et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24: 1203-12.
9. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
10. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-8.
11. Kuritzkes DR, Lalama CM, Ribaudo HJ et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197: 867-70.
12. Wittkop L, Günthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (30 November 2011, date last accessed).
14. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
15. Oette M, Kaiser R, Döumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006; 41: 573-81.
16. Shet A, Berry L, Mohri H et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006; 41: 439-46.
17. Fox J, Dustan S, McClure M et al. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 2006; 7: 477-83.
18. Poggensee G, Kücherer C, Werning J et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 2007; 8: 511-9.
19. Jakobsen MR, Tolstrup M, Søgaard OS et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 2010; 50: 566-73.
20. Hamers RL, Siwale M, Wallis CL et al. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010; 55: 95-101.
21. Palumbo P, Lindsey JC, Hughes MD et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-20.
22. Yang CH, Yang SY, Shen MH et al. The changing epidemiology of prevalent diagnosed HIV infections in Taiwan, 1984-2005. Int J Drug Policy 2008; 19: 317-23.
23. Chang SY, Chen MY, Lee CN et al. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 2008; 61: 689-93.
24. De Mendoza C, Garrido C, Corral A et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 2007; 23: 879-85.
25. Vercauteren J, Deforche K, Theys K et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008; 5: 12.
26. Chang SY, Sheng WH, Lee CN et al. Molecular epidemiology of HIV type 1 subtypes in Taiwan: outbreak of HIV type 1 CRF07_BC infection in intravenous drug users. AIDS Res Hum Retroviruses 2006; 22: 1055-66.
27. Johnson VA, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156-63.
28. Zazzi M, Prosperi M, Vicenti I et al. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother 2009; 64: 616-24.
29. Frentz D, Boucher CA, Assel M et al. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS ONE 2010; 5: e11505.
30. McKinnell JA, Willig JH, Westfall AO et al. Antiretroviral prescribing patterns in treatment-naïve patients in the United States. AIDS Patient Care STDS 2010; 24: 79-85.
31. Godin G, Gagné C, Naccache H. Validation of a self-reported questionnaire assessing adherence to antiretroviral medication. AIDS Patient Care STDS 2003; 17: 325-32.
32. Lepri AC, Miller V, Phillips AN et al. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS 2001; 15: 47-54.
33. Smith CJ, Staszewski S, Sabin CA et al. Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr 2004; 37: 1155-9.
34. Chaix ML, Desquilbet L, Descamps D et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 2007; 12: 1305-10.
35. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-35.
36. Bertagnolio S, Kelley K, Hassani AS et al. Surveillance of transmitted and acquired HIV drug resistance using WHO surveys in resource-limited settings. In: Oral Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Oral Abstract 52, p. 90. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
37. WHO. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. WHO Press, WHO, November 2009.
38. Li JZ, Paredes R, Ribaudo HJ et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305: 1327-35.
39. Sax PE, Islam R, Walensky RP et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-23.